TSXV - Delayed Quote ? CAD Rakovina Therapeutics Inc. (RKV.V) Follow Compare 0.0750 -0.0050 (-6.25%) At close: 12:53 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancerVANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki? generative artificial intelligence (AI) platform for drug discovery, announced today a research colla GlobeNewswire ? last month RKVTF Rakovina Therapeutics Second-Quarter Loss Widens on Higher Spending Rakovina Therapeutics Second-Quarter Loss Widens on Higher Spending PREMIUM MT Newswires ? last month RKVTF Rakovina Therapeutics Announces 2024 Q2 Financial Results?and Provides Corporate Update All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the second quarter ending June 30, 2024, and provides an update to corporate activities. "We are thrilled by the rapid progress and strategic advancemen GlobeNewswire ? last month RKVTF Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement All dollar amounts reflected in Canadian dollars unless otherwise stated.VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024, July 19, 2024, and July 22, 2024, the Company has closed its previously announced over-subscribed non-bro GlobeNewswire ? 2 months ago RKVTF Rakovina Therapeutics Provides Update on Previously Announced Private Placement All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024 and July 19, 2024, the Company has received subscriptions for an aggregate of $2,000,000 worth of units o GlobeNewswire ? 2 months ago RKVTF Rakovina Therapeutics Announces Second Upsizing of Private Placement All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press releases dated May 23, 2024 and June 20, 2024, that to accommodate additional indications of interest it will upsize the previously announce GlobeNewswire ? 3 months ago RKVTF Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press release dated May 23, 2024, that it has received subscriptions totalling $1.7 million for its previously announced $1.5 million private placeme GlobeNewswire ? 3 months ago RKVTF Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the first quarter of 2024 ending March 31, and provides an update to corporate activities. “This year has started with significant changes for Rakovina T GlobeNewswire ? 4 months ago RKVTF Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 12.0 per cent unsecured convertible debentures of the Company (the “Debentures”) have elected to receive common sha GlobeNewswire ? 4 months ago RKVTF Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5 million at a purchase price of $0.10 per Unit. This includes l GlobeNewswire ? 4 months ago RKVTF Rakovina expands collaborations to leverage AI platform Rakovina has expanded research collaborations with Pharma Inventor and the University of British Columbia to identify novel drug candidates. Medical Device Network ? 5 months ago RKVTF Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc.VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its re GlobeNewswire ? 5 months ago RKVTF Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and provided a corporate update. 2023 Highlights and Recent Developments On March 27, 2024 we announced a collaboration agreement with Dr. Artem Cherkasov granting R GlobeNewswire ? 5 months ago RKVTF Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D GlobeNewswire ? 6 months ago RKVTF Rakovina Therapeutics To Host Informational Webinar on April 3, 2024 Announces Capital Markets Advisory AgreementVANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, will be hosting an informational webinar on Wednesday, April 3, 2024. The Rakovina leadership team and members of the scientific team will host the co GlobeNewswire ? 6 months ago RKVTF Rakovina Therapeutics Announces Strategic Pivot to AI Company Leveraging Deep Docking AI Drug Discovery PlatformVANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce a strategic evolution in its business model that will place the Company at the forefront of artificial intelligence-driven (AI GlobeNewswire ? 6 months ago RKVTF Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial results for the quarter ended September 30, 2023, and provided a corporate update. Corporate highlights during the past quarter included: On November 27, 2023, we announced the appointment of Prof. Artem Cher GlobeNewswire ? 10 months ago RKV.V -6.25% Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response inhibitors (DDRi) to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Artem Cherkasov to the Company’s Scientific Advisory Board. Prof. Cherkasov is a Professor in the Department of Urologic Sciences, Faculty of Medicine at the University of B GlobeNewswire ? 10 months ago RKV.V -6.25% Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response (DDR) inhibitors to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to its Scientific Advisory Boa GlobeNewswire ? 10 months ago RKV.V -6.25% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return RKV.V S&P/TSX Composite index YTD -11.76% +17.96% 1-Year -21.05% +29.34% 3-Year -62.50% +16.68%
